Security key
90240B106
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 56,830,609
- Total 13F value
- $1,493,991,866
- Share change
- +133,090
- SEC-reported price per share
- $26.29
- Number of holders
- 133
- Value change
- +$12,760,989
- Number of buys
- 67
- Number of sells
- 47
- Shares outstanding
- 59,524,560
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
133
Top holders
10
TYRA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Tyra Biosciences, Inc. SEC filings
Tyra Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 90240B106
Recent filing periods:
Ownership snapshot
Top reported holders of TYRA - Tyra Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TCG Crossover GP I, LLC
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 5.7%
13D/G row: TCG Crossover GP I, LLC
Showing 1-6 of 15 holder rows.
Quick read
TCG Crossover GP I, LLC leads the comparable SEC ownership view at 5.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TCG Crossover GP I, LLC's linked filing trail.
Comparable ownership
Top 5
TCG Crossover GP I, LLC
5.7%
Vestal Point Capital, LP
4.5%
BIOTECHNOLOGY VALUE FUND L P
4%
RA CAPITAL MANAGEMENT, L.P.
20%
Alta Partners Management Company,...
6.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TCG Crossover GP I, LLC |
13D/G
|
5.7%
|
$29,792,499
2,898,103 shares
|
$0 | 27 Feb 2025 |
| Vestal Point Capital, LP |
13D/G
13F
Company
|
4.5%
|
$33,925,750
2,425,000 shares
|
-$6,363,058 | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
4%
|
$64,574,633
2,127,665 shares
|
-$55,131,655 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
20%
|
$170,658,764
12,198,625 shares
|
— | 30 Sep 2025 |
| Alta Partners Management Company, L.P. |
13F
Company
|
6.9%
|
$57,083,341
4,080,296 shares
|
— | 30 Sep 2025 |
| Nextech Invest, Ltd. |
13F
Company
|
6.8%
|
$56,741,495
4,055,861 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
133
Shares
56,830,609
Rows available
133
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
115
Q4 2025 holders
133
Holder diff
18
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend